Hendon Partners
Valuation

Home Health Value-Based Purchasing (HHVBP) and Agency Valuation: A 2026 M&A Guide

Neli Gertner
#HHVBP#value-based-purchasing#home-health#valuation#quality#CMS

Most home health owners think of quality scores as a clinical scoreboard — something the director of nursing watches, not something that shows up in an enterprise value. Under the expanded Home Health Value-Based Purchasing (HHVBP) Model, that is no longer true. Quality is now wired directly into your Medicare payments, and through them into your EBITDA and your sale multiple.

This guide explains what the expanded HHVBP Model is, how the payment adjustment flows through to valuation, what buyers actually diligence, and what sellers can do about their score before they go to market.


What the Expanded HHVBP Model Is

HHVBP ties a portion of Medicare home health fee-for-service payments to performance on quality. The original HHVBP Model ran in nine states from 2016 through 2021. The expanded model went nationwide beginning in CY2023, making every Medicare-certified home health agency in the country a participant.

The mechanics every buyer’s diligence team already understands:

  • A Total Performance Score (TPS). Each agency receives an annual TPS that summarizes its quality performance.
  • A payment adjustment of up to ±5%. The TPS translates into an upward or downward adjustment on the agency’s Medicare home health payments, applied two years after the performance year.
  • Cohort-based, budget-neutral competition. Agencies are scored within size-based cohorts (larger-volume and smaller-volume) and effectively compete against comparable peers. Your score is relative, not an absolute pass/fail — being merely “fine” while your cohort improves can still produce a downward adjustment.

The practical takeaway: HHVBP is not a bonus program you can ignore. It is a permanent feature of Medicare home health economics that moves real dollars on your top line.


How the Adjustment Flows to EBITDA

Home health is a thin-margin business. Most agencies operate on single-digit to low-teens EBITDA margins, so a payment adjustment measured in percentage points of Medicare FFS revenue is not a rounding error — it is a direct hit or boost to the bottom line.

Consider an agency with meaningful traditional Medicare fee-for-service revenue:

  • A positive TPS-driven adjustment lifts FFS revenue with essentially no incremental cost, dropping almost entirely to EBITDA.
  • A negative adjustment cuts FFS revenue the same way — straight out of EBITDA.

When a buyer capitalizes your earnings at a multiple, that quality-driven swing is multiplied. A few points of margin created or destroyed by HHVBP, capitalized at a home health multiple, can move enterprise value by far more than the raw dollar adjustment. This is why sophisticated acquirers model your TPS trajectory, not just your trailing financials.


The Measures That Drive Your Score

The TPS is assembled from three categories of measures, and each tells a buyer something different about your business:

  • OASIS-based (clinical) measures — improvement in mobility, self-care, and functional status. These reflect clinical program strength and care management discipline.
  • Claims-based measures — acute-care hospitalization and emergency department utilization. These are watched closely because they also drive your standing with hospital and Medicare Advantage referral partners.
  • HHCAHPS patient-experience survey measures — how patients rate your care and communication. These correlate with referral durability and reputation.

Scoring rewards both achievement (performance against a national benchmark) and improvement (performance against your own baseline). A practical consequence: an agency that starts from a low baseline and improves can still earn meaningful points — useful framing for a seller who has been investing in quality recently.

Alongside HHVBP, buyers will pull your public Quality of Patient Care star rating and HHCAHPS survey star rating. These star ratings are not the HHVBP score itself, but they are visible to referral sources and acquirers and reinforce the same story about clinical strength.


How Buyers Diligence HHVBP

In a 2026 Medicare home health diligence process, expect acquirers to:

  1. Pull your TPS history and payment adjustments to quantify the revenue effect already baked into your numbers — and to separate “real” margin from a temporary HHVBP tailwind or drag.
  2. Trend your hospitalization and ED-use rates as both a quality signal and a referral-risk signal.
  3. Review star ratings and HHCAHPS to assess reputation and referral durability.
  4. Test the durability of a strong score — is high performance the product of a repeatable clinical program, or a one-year anomaly?
  5. Model rate risk into the multiple, discounting agencies whose scores are weak, volatile, or declining.

A clean, improving quality story shortens diligence and supports the top of your valuation range. A weak or erratic one invites reps, holdbacks, and a discount.


The Valuation Read-Through

For a Medicare-certified home health agency, quality performance has become one of the clearest non-financial value drivers, sitting alongside payer mix and Medicare Advantage exposure:

  • Premium signals: a consistently strong TPS, a positive payment adjustment, low hospitalization rates, high star ratings, and a documented, repeatable clinical program.
  • Discount signals: a weak or declining TPS, a negative adjustment, elevated hospitalization or ED use, and quality that depends on a single clinician or a one-off effort.

If your agency carries significant Medicare Advantage exposure as well, the two stories compound — MA already pressures per-episode rates, and a weak HHVBP score adds rate risk on the FFS side. For the full picture on the MA side of that equation, see our guide on Medicare Advantage and home health valuation, and on the broader payer question, payer mix and home care valuation.


What Sellers Should Do Before Going to Market

Quality scores move slowly, so the time to act is well before a sale process begins:

  • Know your numbers. Pull your current TPS, your payment adjustment, your hospitalization and ED-use rates, and your star ratings — and be ready to explain the trend.
  • Document the program, not just the result. Buyers pay for repeatability. A written care-management protocol, OASIS accuracy process, and HHCAHPS follow-up routine make a strong score defensible.
  • Fix obvious drags early. Acute-care hospitalization is often the highest-leverage measure; targeted care-transition work can move it within a few quarters.
  • Connect quality to staffing stability. Scores and outcomes track closely with caregiver continuity — see caregiver turnover and home care valuation.
  • Tell the story in the CIM. Quality should be a headline section of your marketing materials, not buried in an appendix.

Deal Structure: Does Your Score Travel?

Because HHVBP performance and the resulting adjustment attach to your CMS Certification Number (CCN), deal structure matters:

  • In a stock or equity sale, the entity and its CCN continue, so the agency’s HHVBP standing — and its quality history — generally carries forward to the buyer.
  • In an asset sale where the buyer enrolls under a new CCN, the HHVBP history can reset, which changes how a buyer values the quality-driven portion of revenue.

This mirrors the structuring logic that already governs Medicare certification in a sale. For the mechanics of how certifications move, see selling a Medicare-certified home health agency and our overview of asset sale vs. stock sale.


The Bottom Line

HHVBP turned home health quality from a clinical scoreboard into a financial one. Your Total Performance Score now influences your Medicare revenue, your EBITDA, and — once a buyer capitalizes that EBITDA — your enterprise value. In 2026, the agencies that command premium multiples are the ones that can show a strong, improving, well-documented quality story and connect it directly to durable Medicare revenue.

If you own a Medicare-certified home health agency and are thinking about a sale in the next 12 to 24 months, your quality performance is part of your valuation today — not just your compliance file. To understand how your HHVBP standing and the rest of your profile translate into a number, book a free confidential call with our team, or explore our Medicare-certified home health M&A guidance.

Frequently Asked Questions

What is the HHVBP Model in home health?
+
The Home Health Value-Based Purchasing (HHVBP) Model is a Medicare program that ties a portion of a home health agency's fee-for-service payments to its quality performance. The expanded model went nationwide in CY2023, after a 9-state original model that ran from 2016 through 2021. Each agency receives a Total Performance Score, and that score determines a payment adjustment of up to plus or minus 5% applied to its Medicare home health payments two years later.
How much can HHVBP change my Medicare payments?
+
The expanded HHVBP Model applies a maximum upward or downward payment adjustment of 5%. Because home health is a thin-margin business, a swing of several percentage points on Medicare fee-for-service revenue can move EBITDA materially — which is exactly why buyers treat your Total Performance Score as a revenue-quality and margin-durability signal rather than a compliance detail.
How is the HHVBP Total Performance Score calculated?
+
The Total Performance Score (TPS) is built from three categories of measures: OASIS-based (clinical) measures, claims-based measures such as acute-care hospitalization and emergency department use, and HHCAHPS patient-experience survey measures. Agencies earn points for both achievement against a benchmark and improvement over their own baseline, and they are scored within size-based cohorts so they compete against comparable peers.
Does my HHVBP score transfer when I sell my agency?
+
It depends on deal structure. HHVBP performance and the resulting payment adjustment are tied to the agency's CMS Certification Number (CCN). In a stock or equity sale, the entity and its CCN continue, so the agency's HHVBP standing generally carries forward. In an asset sale where the buyer enrolls under a new CCN, the HHVBP history can reset — a point buyers weigh when they structure the transaction and price quality-driven revenue.
Can a strong quality score increase my agency's valuation?
+
Yes. A consistently strong Total Performance Score signals a positive HHVBP payment adjustment, lower hospitalization rates, durable referral relationships, and a defensible Medicare revenue base — all of which support a higher multiple. Conversely, a weak or declining score introduces rate risk and referral risk that buyers discount. Quality performance has become one of the clearest non-financial value drivers in Medicare home health M&A.

Newsletter

Stay ahead of home care M&A

Receive new articles, EBITDA benchmark updates, and deal intelligence directly in your inbox. No spam — unsubscribe anytime.

Join 1,200+ home care executives. Unsubscribe anytime.